Make your own free website on



ACS (American Cancer Society) Cancer Facts and Figures 1995.

Adachi N. Kobayashi M. Koyama H. Cell cycle-dependent regulation of the mouse DNA topoisomerase IIalpha gene promoter. Biochem Biophys Res Commun 1997 Jan 3;230(1):105-109

Aebi S. Kurdi-Haidar B. Gordon R. Cenni B. Zheng H. Fink D. Christen RD. Boland CR. Koi M. Fishel R. Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Research. 56(13):3087-90, 1996 Jul 1.

Allinger NL. Advances in Physical Organic Chemistry 13:1 1976

Anderson RD. Berger NA. Mutagenicity and carcinogenicity of topoisomerase interactive agents. Mutation Research 309:109-42 1994.

Annand RR. Kontoyianni M. Penzotti JE. Dudler T. Lybrand TP. Gelb MH (1996). Active site of bee venom phospholipase A2: the role of histidine-34, aspartate-64 and tyrosine-87. Biochemistry. 35(14):4591-601.

Annand RR. Kontoyianni M. Penzotti JE. Dudler T. Lybrand TP. Gelb MH. Active site of bee venom phospholipase A2: the role of histidine-34, aspartate-64 and tyrosine-87. Biochemistry. 35(14):4591-601, 1996 Apr 9.

Antoine R. Locht C. The NAD-glycohydrolase activity of the pertussis toxin S1 subunit. Involvement of the catalytic HIS-35 residue. Journal of Biological Chemistry. 269(9):6450-7, 1994 Mar 4.

Appel RD. Bairoch A. Hochstrasser DF. A new generation of Information Retrieval Tools for Biologists. Trends Biochem Sci 19:258 1994.

Asano T. An T. Mayes J. Zwelling LA. Kleinerman ES. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochemical Journal. 319 ( Pt 1):307-13, 1996c.

Asano T. An T. Zwelling LA. Takano H. Fojo AT. Kleinerman ES. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncology Research. 8(3):101-10, 1996b.

Asano T. Zwelling LA. An T. McWatters A. Herzog CE. Mayes J. Loughlin SM. Kleinerman ES. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. British Journal of Cancer. 73(11):1373-80, 1996a.

Asimakopoulos FA. White NJ. Nacheva E. Green AR. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood. 84(9):3086-94, 1994 Nov 1.

Baguley BC. Holdaway KM. Finlay GJ. Modulation of protein-DNA interactions by intercalating and nonintercalating agents. P355-67 in "Molecular Basis of Specificity in Nucleic Acid-Drug Interactions" ed B Pullman & J Jortner. Kluwer 1990.

Bailar JC. Gornik HL. Cancer Undefeated. New England Journal of Medicine 336:1569-74 1997.

Banasik M. Komura H. Shimoyama M. Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl) transferase. Journal of Biological Chemistry 267:1569-75 1992.

Bauman ME. Holden JA. Brown KA. Harker WG. Perkins SL. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas. Mod Pathol 1997 Mar;10(3):168-175

Baylin SB. Herman JG. Graff JR. Vertino PM. Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 72:141-96 1998.

Bechert T. Diekmann S. Arndt-Jovin DJ. Human 170 kD and 180 kD topoisomerases II bind preferentialy to curved and left-handed linear DNA. Journal of Biomolecular Structure & Dynamics 12:605-23 1994.

Beck WT. DNA Topoisomerases and Tumor Cell Resistance to Their Inhibitors p487-501 in "Principles of Antineoplastic Drug Development and Pharmacology" ed Schilsky RL. Milano GA. Ratain MJ. Marcel Dekker 1996.

Berger JM. Gamblin SJ. Harrison SC. Wang JC. Structure and mechanism of DNA topoisomerase II Nature. 379(6562):225-32, 1996 Jan 18.

Berger MS. Locher GW. Saurer S. Gullick WJ. Waterfield MD. Groner B. Hynes NE. Correlation of c-erbB2 gene Amplification and protein expression in human breast carcinoma with modal status and nuclear grading. Cancer Residues 4:1238-43 1988.

Bernardi R. Negri C. Donzelli M. Guano F. Torti M. Prosperi E. Scovassi AI. Activation of poly(ADP-ribose)polymerase in apoptotic human cells. Biochimie. 77(5):378-84, 1995.

Bernhardt PV. Comba P. Inorganic Chemistry 31:2638 1992

Beveridge DL. DiCapua FM Annual Reviews of Biophysical and Biophysical Chemistry 18:431 1989

Biersack H. Jensen S. Gromova I. Nielsen IS. Westergaard O. Andersen AH. Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8288-8293

Bisht KS. Uma Devi P. Hyperthermia in cancer research: current status. [Review] Indian Journal of Experimental Biology. 34(12):1183-9, 1996 Dec.

Boege F. Kjeldsen E. Gieseler F. Alsner J. Biersack H. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution. European Journal of Biochemistry. 218(2):575-84, 1993 Dec 1.

Boege F. Straub T. Kehr A. Boesenberg C.Christiansen K. Andersen A. Jakob F. Kohrle J. Medizinische Poliklinik. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. Journal of Biological Chemistry. 271(4):2262-70, 1996 Jan 26.

Boeyens JCA. Environmental Factors in Molecular Modelling. p99-103 in "Fundamental Principles of Molecular Modeling" ed Gans W. Amann A & Boeyens JCA; Plenum 1996.

Bonfoco E. Zhivotovsky B. Rossi AD. Aguilar-Santelises M. Orrenius S. Lipton SA. Nicotera P. BCL-2 delay apoptosis and PARP cleavage induced by NO donors in GT1-7 cells. Neuroreport. 8(1):273-6, 1996 Dec 20.

Brana M & Sanz A; "Synthesis and Cytostatic Activity of benzisoquinolin-1,3-diones: SAR" European Journal of Medicinal Chemistry 16,207-12 1981

Brana M etal (1980) "Synthesis and modes of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid; Cancer Chemother Pharmacol 4, 61-66

Brana MF. Castellano JM. Roldan CM. Santos A. Vazquez D. Jimenez A. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid. Cancer Chemotherapy & Pharmacology. 4(1):61-6, 1980.

Brandt TL. Fraser DJ. Leal S. Halandras PM. Kroll AR. Kroll DJ. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter. Journal of Biological Chemistry. 272(10):6278-84, 1997 Mar 7.

Bronner CE. Baker SM. Morrison PT. Warren G. Smith LG. Lescoe MK. Kane M. Earabino C. Lipford J. Lindblom A. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368(6468):258-61, 1994 Mar 17.

Brown LS. Sasaki J. Kandori H. Maeda A. Needleman R. Lanyi JK. Glutamic acid 204 is the terminal proton release group at the extracellular surface of bacteriorhodopsin. Journal of Biological Chemistry. 270(45):27122-6, 1995 Nov 10.

Bryant C. McElroy WD. Pg 291-304 in: "Chemistry and Biochemistry of Flavoenzymes" ed Franz Muller. CRC press. 1991.

Bryskier A. Chantot JF. Classification and structure activity relationships of fluoroquinolones. Drugs 49 (suppl) 2:16-28 1995.

Bugg BY. Danks MK. Beck WT. Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 88(17):7654-8, 1991 Sep 1.

Cain BF. Atwell GJ. Denny WA. Potential antitumor agents. Journal of Medicinal Chemistry 18:1110-7 1975.

Campain JA. Gottesman MM. Pastan I. A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry. 33(37):11327-32, 1994 Sep 20.

Campain JA. Slovak ML. Schoenlein PV. Popescu NC. Gottesman MM. Pastan I. Acquisition of multiple copies of a mutant topoisomerase IIa allele. Somatic Cell and Molecular Genetics 21:451-71 1995.

Capranico G. Zunino F. Kohn KW. Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry. 29(2):562-9, 1990 Jan 16.

Chamoux JJ. ‘Topoisomerase I Mechanism’ in "DNA Topology and its Biological Effects" ed by Cozzarelli NR & Wang JC. Cold Spring Harbor Press 1990.

Chan VT. Ng SW. Proceeding of the American Association Cancer Research 33:451 1992

Chan VT. Ng SW. Eder JP. Schnipper LE. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. Journal of Biological Chemistry. 268(3):2160-5, 1993 Jan 25.

Chen KX. Gresh N. Pullman B. A theoretical study of the intercalative binding of the anti-tumor drug anthrapyrazole. Anti-Cancer Drug Design 2:79-84 1987.

Chen M. Beck WT. Teniposide resistant CEM cells, which express mutant DNA topoisomerase IIa, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross resistance and reveal aberrant functions of the mutant enzyme. Cancer Research 53(24):5946-53 1993.

Chen M & Beck WT. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26 resistant human leukemic CEM sublines. Oncology Research 7:103-11 1995.

Chen Q. Deady LW. Baguley BC. Denny WA. Electron deficient DNA intercalating agents as antitumor drugs: aza analogues of 2-dimethyl-amino-ethyl-acridine-4-carboxamide. Journal of Medicinal Chemistry 37:593-7 1994.

Cho SJ. Tropsha A. Suffness M. Cheng YC. Lee KH. Antitumor agents. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach. Journal of Medicinal Chemistry. 39(7):1383-95, 1996 Mar 29.

Chresta CM. Masters JR. Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Research. 56(8):1834-41, 1996 Apr 15.

Comba P & Hambley TW. "Molecular Modeling". VCH 1995

Comba P. Coordination Chemistry Review 123:1 1993

Cornarotti M. Capranico G. Bohm S. Oriana S. Spatti GB. Mariani L. Ballabio G. Zunino F. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 67(4):479-484 1996

Cortes J. O’Brien S. Kantarjian H. Cork A. Stass S. Freireich EJ. Keating M. Pierce S. Estey E. Abnormalities in the long arm of chromosome 11q in patients with de novo and secondary acute myelogenous leukemias. Leukemia 8:2174-8 1994].

Cunningham JM. Francis GE. Holland MJ. Pirollo KF. Chang EH. Aberrant DNA topoisomerase II activity. British Journal of Cancer. 63(1):29-36, 1991 Jan.

Daggett V. Kollman PA. Kuntz ID. Molecular dynamics simulations of small peptides: dependence on dielectric model and pH. Biopolymers 31:285-304 1991

Danks MK. Warmoth MR. Friche E. Granzen B. Bugg BY. Harker WG. Zwelling LA. Futscher BW. Suttle DP. Beck WT. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Research 53(6):1373-9, 1993 Mar 15.

Danks MK. (93b) Beck WT. Suttle DP. Topoisomerase IIa mutation in Leukemic Cells from a Patient with Lineage Switch AML. Proceedings of the American Association of Cancer Research 34:333 & 1982 1993

Davies SM. Robson CN. Davies SL. Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epopodophyllotoxins. Journal of Biological Chemistry 263:17724-9 1988.

DeVito SC. Garrett RL. "Designing Safer Chemicals: Green Chemistry for Pollution Prevention" American Chemical Society 1996.

Dorshow JH. Locker GY. Meaers CE. Enzymatic Defenses in the Mouse Heart Against Reactive Oxygen Metabolites. Journal of Clinical Investigation 65:128-35 1980.

Drabkin H. Kao FT. Hartz. J. Hart I. Gazdar A. Weinberger C. Evans R. Gerber M. Localization of human ERB42 to 3p22-3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. Proc Natl Acad Sci. 85:9258-62 1988.

Drake FH. Hofmann GA. Bartus JO. Mattern MR. Crooke ST. Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28(20):8154-60 1989a.

Drake FH. Hofmann GA. Mong SM. Bartus JO. Hertzberg RP. Johnson RK. Mattern MR. Mirabelli CK. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Research. 49(10):2578-83, 1989b.

Eder JP Jr. Chan VT. Niemierko E. Teicher BA. Schnipper LE. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. Journal of Biological Chemistry. 268(19):13844-9, 1993 Jul 5.

Ehrig T. Hurley TD. Edenberg HJ. Bosron WF. General base catalysis in a glutamine for histidine mutant at position 51 of human liver alcohol dehydrogenase. Biochemistry. 30(4):1062-8, 1991 Jan 29.

Einisto P. Watanabe M. Ishidate M. Nohmi T. Mutagenicity of 30 chemicals in Salmonella typhimurium strains possessing different nitroreductase or O-acetyltransferase activities. Mutation Research 259:95-102 1991.

Engelman DM. Steitz TA. Goldman A. Identifying Non-polar Transbilayer Helices in Amino Acid Sequences of Membrane Proteins. Annual Review of Biophysical Chemistry 15.321 1986

Epstein RE & Smith PJ Bio Bio Res Comm 160:12-17 1989

Expasy web server at or

Fan S. el-Deiry WS. Bae I. Freeman J. Jondle D. Bhatia K. Fornace AJ Jr. Magrath I. Kohn KW. O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Research. 54(22):5824-30, 1994 Nov 15.

Fesen MR. Pommier Y. Leteurtre F. Hiroguchi S. Yung J. Kohn KW. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester and related compounds. Biochemical Pharmacology 48(3):595-608 1994.

Fraser DJ. Brandt TL Kroll DJ. Topoisomerase IIa Promoter Trans Activation Early in Monocytic Differentiation of HL-60 Human Leukemia Cells. Molecular Pharmacology 47:696-706 1995].

Friesner RA. Accuracy of molecular modeling force fields: Insights and new developments from ab initio quantum chemical calculations. Abstract #59, Division of Computers in Chemistry, 215th ACS national meeting, Dallas Tx 3/29-4/2 1998.

Froelich-Ammon SJ. Burden DA. Patchan MW. Elsea SH. Thompson RB. Osheroff N. Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase. J Biol Chem. 270(47):28018-21, 1995 Nov 24.

Futreal PA. Liu Q. Shattuck-Eidens D. Cochran C. Harshman K. Tavtigian S. Bennett LM. Haugen-Strano A. Swensen J. Miki Y. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266(5182):120-2, 1994 Oct 7.

Garinther WI. Schultz MC. Topoisomerase function during replication-independent chromatin assembly in yeast. Mol Cell Biol 1997 Jul;17(7):3520-3526

Gasser SM. Laemmli UK. A Glimpse at Chromosomal Order. Trends in Genetics 3:16-22 1987.

Giaccone G. Gazdar AF. Beck H. Zunino F. Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Research 52:1666-74 1992.

Gianni L. Cardin BJ. Myers CE. The biochemical basis of anthracyclin toxicity and antitumor activity. Reviews Biochemistry & Toxicology 5:1-82 1982

Gieseler F. Boege F. Ruf B. Meyer P Wilms K. Molecular Pathways of Topoisomerase II Regulation and Consequences for Chemotherapy. Acute Leukemias IV:299-304 1994. Gieseler F. Glasmacher A. Kampfe D. Nubler V. Valsamas S. Kunze J. Clark M. Topoisomerase II activities in Human Leukemic Cells. Acute Leukemias VI: 538-42 1997b.

Gieseler F. Topoisomerases-From Basic Research to Clinical Implications. Acute Leukemias V: 89-93 1996.

Gieseler F. Glasmacher A. Kampfe D. Zernak C. Valsamas S. Kunze J. Clark M. Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias. Recent Results in Cancer Research. 143:321-7, 1997.

Gilli P. Ferretti V. Gilli G. Hydrogen Bonding Models: Their Relevance to Molecular Modeling. P119-41 in "Fundamental Principles of Molecular Modeling" ed Gans W. Amann A & Boeyens JCA; Plenum 1996.

Gilson MK. Theory of Electrostatic Interactions in macromolecules. Current Opinion in Structural Biology 5:216-23 1995.

Giunciuglio D. Culty M. Fassina G. Masiello L. Melchiori A. Paglialunga G. Arand G. Ciardiello F. Basolo F. Thompson EW. et al. Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer. 63(6):815-22, 1995 Dec 11.

Gohda K. Oka K. Tomita K. Hakoshima T. Crystal structure of RNase T1 complexed with the product nucleotide 3'-GMP. Structural evidence for direct interaction of histidine 40 and glutamic acid 58 with the 2'-hydroxyl group of the ribose. Journal of Biological Chemistry. 269(26):17531-6, 1994 Jul 1.

Goodford PJ. Journal of Medicinal Chemistry 28:849 1985. Also, Wade RC & Goodford PJ. Further development of hydrogen bond fuctions. Journal of Medicinal Chemistry 36:148-56 1993.

Grabowski D & Ganapathi R. Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug resistant L1210 mouse leukemia cells. Annals of the New York Academy of Science 803:306-7 1996.

Gururasad K. Reddy BVB. Pandit MW. Protein Engineering 4:155-61 1990.

Hanks SK. Quinn AM. Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52 1988.

Hansch C. Leo A. "Exploring QSAR" ACS 1995. quote on page 377

Hashimoto S. Danks MK. Chatterjee S. Beck WT. Berger NA. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II Oncol Res. 7(1):21-9, 1995.

Hemminki A. Peltomaki P. Mecklin JP. Jarvinen H. Salovaara R. Nystrom-Lahti M. de la Chapelle A. Aaltonen LA. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet. 8(4):405-10, 1994 Dec.

Hinds M. Deisseroth K. Mayes J. Altschuler E. Jansen R. Ledley FD. Zwelling LA. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 51(17):4729-31, 1991 Sep 1.

Hochhauser D. Stanway CA. Harris AL. Hickson ID. Cloning and characterization of the 5’ flanking region of the human topoisomerase IIa gene. Journal of Biol Chemistry 267:18961-5 1992]

Hollings PE. Molecular heterogeneity at the breakpoints of smaller 20q deletions. Genes Chromosomes Cancer. 11(1):21-8, 1994 Sep.

Holm C. Goto T. Wang JC. Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 41(2):553-63, 1985 Jun.

Hopfinger A & Tokarski JS. 3D-QSAR Analysis. P105-64 in "Practical Application of Computer Aided Drug Design" ed Charifson PS. Dekker 1997.

Houlbrook S. Harris AL. Carmichael J. Stratford IJ Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Research Jul;16(4A):1603-1610 1996

Howard MT. Neece SH. Matson SW. Dreuzer KN. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proceedings of the National Academy of Science 91:12031-5 1994.

Hsiang Y-H. Wu H. Liu LF. Proliferation dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Research 47:3230-35 1988.

Hsiang YH. Jiang JB. Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Molecular Pharmacology. 36(3):371-6, 1989.

Hsiang YH. Wu HY. Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Research. 48(11):3230-5, 1988.

Hsiung Y. Elsea SH. Osheroff N. Nitiss JL. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J Biol Chem. 270(35):20359-64, 1995 Sep 1.

Hsiung Y. Jannatipour M. Rose A. McMahon J. Duncan D. Nitiss JL. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res. 56(1):91-9, 1996 Jan 1.

Ikai A. Thermostability and aliphatic index of globular proteins. Journal of Biochemistry. 88(6):1895-8, 1980 Dec.

Inaba M; Mitsuhashi J; Kawada S; Nakano H Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85: 187-93 1994

Jager F. Fahmy K. Sakmar TP. Siebert F. Identification of glutamic acid 113 as the Schiff base proton acceptor in the metarhodopsin II photointermediate of rhodopsin. Biochemistry. 33(36):10878-82 1994

Jannatipour M. Liu YX. Nitiss JL. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J Biol Chem. 268(25):18586-92, 1993 Sep 5.

Jarvinen TA. Kononen J. Pelto-Huikko M. Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol. 148(6):2073-82, 1996 Jun.

Jeffrey GA & W Saenger. Hydrogen Bonding in Biological Structures. Springer Verlag 1991

Jenkins JR. Ayton P. Jones T. Davies SL. Simmons DL. Harris AL. Sheer D. Hickson ID. Isolation of cDNA Clones Encoding the Beta Isozyme of Human DNA Topoisomerase II and Localization of the Gene to Chromosome 3p24. Nucleic Acids Research 20: 5587-92 1992.

Jensen PB. Sorensen BS. Demant EJF. Sehested M. Jensen PS. Vindelov L. Hansen HH. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and AMSA in human small cell lung cancer cell lines and on topoisomerase II mediated DNA cleavage. Cancer Research 50(11):3311-16 1990.

Jorgensen WL & Ravimohan C. Journal of Chemical Physics 83:3050 1985

Joseph-McCarthy D. Rost LE. Komives EA. Petsko GA. (1994) Crystal structure of the mutant yeast triosephosphate isomerase in which the catalytic base glutamic acid 165 is changed to aspartic acid. Biochemistry. 33(10):2824-9

Kamesaki S. Kamesaki H. Jorgensen TJ. Tanizawa A. Pommier Y. Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Research. 53(18):4251-6, 1993 Sep 15. [erratum 54(11):3074 1994 Jun 1.]

Karlsen F. Rabbitts PH. Sundresan V. Hagmar B. PCR-RFLP studies on chromosome 3p in formaldehyde-fixed, paraffin-embedded cervical cancer tissues. Int J Cancer. 58(6):787-92, 1994 Sep 15.

Kaufmann SH. McLaughlin SJ. Kastan MB. Liu LF. Karp JE. Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res. 51(13):3534-43, 1991 Jul 1.

Keith WN. Douglas F. Wishart GC. McCallum HM. George WD. Kaye SB. Brown R. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. European Journal of Cancer. 29A(10):1469-75, 1993.

Keith WN. Tan KB. Brown R. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes Chromosomes Cancer. 4(2):169-75, 1992 Mar.

Khelifa T. Casabianca-Pignede MR. Rene B. Jacquemin-Sablon A. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors. Molecular Pharmacology. 46(2):323-8, 1994 Aug.

King CR. Fischer PH. Rando RF. Pastan I. The Performance of e23(Fv)Pes, recombinant toxins targeting the erbB2 protein. Seminars in Cancer Biology 7:79-86 1996.

Kohno K. Danks MK. Matsuda T. Nitiss JL. Kuwano M. Beck WT. A Novel Mutation of DNA topoisomerase Iia gene in an etoposide resistant human cancer cell line. Cellular Pharmacology 2:87-90 1995.

Kollman PA. Drug Target Binding Forces p399-412 in "Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition" ed ME Woolff, Wiley-Interscience, New York, 1995

Koo HM. Monks A. Mikheev A. Rubinstein LV Gra-Goodrich M. McWilliams MJ. Alvord WG. Oie HK. Gazdar AF. Paull KD. Zarbl H. Van de Woude GF. Enhanced sensitivity to 1-beta-D-arabinofuranosyl-cytosine and topoisomerase II inhibitors. Cancer Research 56:5211-6 1996.

Koomagi R. Stammler G. Manegold C. Mattern J. Volm M. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett 1996 Dec 20;110(1-2):129-136

Kostrewa D. Winkler FK. Mg2+ binding to the active site of EcoRV endonuclease. Biochemistry 34:683-96 1995

Kubo Proc American Assoc Cancer Research 36:2664 1995

Kuntz ID. Meng EC. Shoichet BK. Structure Based Molecular Design. Accounts of Chemical Research 27:117-23 1994.

Kunze N. Yang GC. Jiang ZY. Hameister H. Adolph S. Wiedorn KH. Richter A. Knippers R. Human Genetics. 84(1):6-10, 1989 Dec.

Kyle J Doolittle RF. J Molec Biology 157:105-32 1982

Lee CH. Liu M. Sie KL. Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Research. 16(4A):1805-11, 1996 Jul-Aug.

Lee CY. Bagdasarian M. Meng MH. Zeikus JG. Catalytic mechanism of xylose (glucose) isomerase from Clostridium thermosulfurogenes. Journal of Biological Chemistry 265(31):19082-90. 1990

Lee MS. Wang JC. Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. Journal of Molecular Biology 223(4):837-43, 1992 Feb 20.

Legha SS. Ring S. Raber M. Felder TB. Newman RA. Krakoff IH. Phase I clinical investigation of benzisoquinolinedione. Cancer Treatment Reports. 71(12):1165-9, 1987 Dec.

Leiby J. Malspeis L. Staubus A. Kraut E. Grever M. Amonafide (NSC 308847): a clinical phase I study of two schedules of administration. Proceedings of the American Association for Cancer Research 29:278 1988

Leitzel K. Teramoto Y. Konrad K. Chinchilli VM. Volas G. Grossberg H. Harvey H. Demers L. Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 13(5):1129-35, 1995 May.

Lerman LS. Structural Consideration in the Interaction of DNA and Acridine. Journal of Molecular Biology 3:18-30 1961.

Leteurtre F. Kohlhagen G. Paull KD. Pommier Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles. Journal of the National Cancer Institute 86:1239-44 1994.

Lewendon A. IA Murray. WV Shaw. MR Gibbs. AG Leslie (1994) Replacement of catalytic histidine-195 of chloramphenicol acetyltransferase. Biochemistry. 33(7):1944-50.

Lindsley JE. Wang JC. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J Biol Chem. 268(11):8096-104, 1993 Apr 15.

Liu LF & Wang. J. Super-coiling of the DNA template during Transcription. Proc Natl Acad Science 84:7024-7 1987

Liu LF. Rowe TC. Yand L. Tewey KM. Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. Journal of Biological Chemistry 258 (24): 15365-70 1983.

Liu LF. DNA Topoisomerase Poisons as Antitumor Drugs; Annual Reviews of Biochemistry 58:351-75 1989

Liu YX. Hsiung Y. Jannatipour M. Yeh Y. Nitiss JL. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents Cancer Res. 54(11):2943-51, 1994

Lock RB. Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996 Sep 1;56(17):4006-4012

Lohri A. Reuter J. Gudat F. Herrmann R. Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J Clin Pathol. 50(1):22-6, 1997.

Lowe SW. Ruley HE. Jacks T. Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74(6):957-67, 1993 Sep 24.

Lu R. Nash HM. Verdine GL. A Mammalian DNA Repair enzyme that excises oxidatively damaged guanines maps to a locus frequently lost in lung cancer. Current Biology 7:397-407 1997.

Lupu R. Cardillo M. Cho C. Harris L. Hijazi M. Perez C. Rosenberg K. Yang D. Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research & Treatment. 38(1):57-66, 1996.

Magnusson PK. Wilander E. Gyllensten U. Analysis of loss of heterozygosity in microdissected tumor cells from cervical carcinoma using fluorescent dUTP labeling of PCR products. Biotechniques. 21(5):844-7, 1996 Nov.

Matsuo KI. Hohno K. Sato S. Uchiumi T. Tanimura H. Yamada Y. Kuwano M. Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Research 53:1085-90 1993.

Mayr CA. Sami SM. Dorr RT. In vitro cytotoxicity and DNA damage production in chinese hamster ovary cells and topoisomerase II inhibition. Anti-Cancer Drugs 8:1-12 1997; Mayr CA. Sami SM. Remers WA. Dorr RT. Intracellular localization of 6 and 7 substituted azonafides. Submitted 1998.

Meczes EL. Marsh KL. Fisher LM. Rogers MP. Austin CA. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast. Cancer Chemotherapy Pharmacology 1997;39(4):367-375

Merz KM & Kollman PA. Free energy perturbation simulations of the inhibition of thermolysin. Journal of the American Chemical Society 111 (15):5649-58 1989

Messmer UK. Reimer DM. Reed JC. Brune B. Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2. FEBS Letters. 384(2):162-6, 1996 Apr 15.

Meyer KN. Kjeldsen E. Straub T. Knudsen BR. Hickson ID. Kikuchi A. Kreipe H. Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. Journal of Cell Biology 1997 Feb 24;136(4):775-788

Miyashita T. Harigai M. Hanada M. Reed JC. Identification of a P53 dependent Negative Response Element in the bcl-2 Gene. Cancer Research 54:3131-5 1994.

Morrison A & Cozzarelli NR. Site specific cleavage of DNA by E. coli DNA gyrase. Cell 17:175-84 1979.

Murphy DS. McHardy P. Coutts J. Mallon EA. George WD. Kaye SB. Brown R. Keith WN. Interphase Cytogenetic Analysis of erbB2 and topoIIa. Int J Cancer 64:18-26. 1995

Naumovski L. Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Molecular & Cellular Biology. 16(7):3884-92, 1996 Jul.

Nelson EM. Tewey KM. Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A. 81(5):1361-5, 1984 Mar.

Nelson WG. Cho KR. Hsiang YH. Liu LF. Coffey DS. Growth-related elevations of DNA topoisomerase II levels found in Dunning R3327 rat prostatic adenocarcinomas. Cancer Res. 47(12):3246-50, 1987 Jun 15.

Neuhausen S. Marshall CJ Loss of Heterozygosity in Familial Tumours from three BRCA1 Linked Kindreds. Cancer Residues. 54:6069-72. 1994

Nitiss JL. Liu YX. Harbury P. Jannatipour M. Wasserman R. Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Research 52:4467-72 1992.

Nitiss JL. Human and yeast top2 mutations conferring altered sensitivity to topoisomerase II targeting agents. The 5th Conference on DNA topoisomerases in therapy. p30 NY. NY 1994b

Nitiss JL. Using yeast to study resistance to topoisomerase II-targeting drugs. [Review] Cancer Chemotherapy Pharmacology 34 Suppl:S6-13, 1994.

Ohashi M. Sugikawa E. Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Japanese Journal of Cancer Research. 86(9):819-27, 1995 Sep.

Osheroff N. Shelton ER. Brutlag DL. DNA Topoisomerase II from Drosophila melanogaster. Journal of Biological Chemistry 258 (15): 9536-43 1983.

Osheroff N. Zachiedrich EL. Gale KC. Catalytic function of DNA topoisomerase II. BioEssays 13:269-73 1991

Osheroff N. Biochemical Basis for the Interactios of Type I and Type II Topoisomerases with DNA. Pharmacology Therapeutics 41:223-41 1989.

Osheroff. N. Role of the Divalent Cation in Topoisomerase II Mediated Reactions. Biochemistry 26:6402-6. 1987

Paddock ML. Rongey SH. Feher G. Okamura MY. (1989) Pathway of proton transfer in bacterial reaction centers: replacement of glutamic acid 212 in the L subunit by glutamine inhibits quinone (secondary acceptor) turnover. Proc NAS 86(17):6602-6.

Paik S. Hazan R. Fisher ER. Sass RF. Fischer B. Redmond C. Schlessinger J. Lippman ME. King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-12 1990.

Parsons JT. Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. [Review] Curr Opin Cell Biol. 9(2):187-92, 1997 Apr.

Patel S. Sprung AU. Keller BA. Heaton VJ. Fisher LM. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol Pharmacol 1997 Oct;52(4):658-666

Patel S. Fisher LM. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer. 67(3):456-63, 1993 Mar.

Pomes R. Willson RC. McCammon JA. Free Energy Simulations of the HyHEL-10/HEL antibody-antigen complex. Protein Engineering 8:663-75 1995.

Pommier Y. DNA Topoisomerase II Inhibitors. p153-74 in "Cancer therapeutics: experimental and clinical agents" ed Teicher BA; Humana Press 1997.

Pommier Y. Covey JM. Kerrigan D. Markovits J. Pham R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Research. 15(16):6713-31, 1987 Aug 25.

Press MF. Cordon-Cardo C. Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-62 1990.

Prolla TA. Abuin A. Bradley A. DNA mismatch repair deficient mice in cancer research. [Review] Semin Cancer Biol. 7(5):241-7, 1996

Ratain MJ. Rosner G. Allen SL. Costanza M. Van Echo DA. Henderson IC. Schilsky RL. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 13(3):741-7, 1995 Mar.

Rawls RL. Optimistic About Antisense. Chemical and Engineering News 75:36 1997 June 2.

Reece Maxwell CRC Critical Review Biochem Molec Bio 26:335 1991

Remers WA. Dorr RT. Sami SM. Alberts DS. Bear S. Mayr CA. Solyom AM. A new class of antitumor agent: 2 substituted-1,2-dihydro-3H-dibenz[deH]isoquinoline-1,3-diones. Current Topics in Medicinal Chemistry 2:45-61 1997.

Richner J. Gerber HA. Locher GW. Goldhirsch A. Gelber RD. Gullick WJ. Berger MS. Groner B. Hynes NE. c-erbB-2 protein expression in node negative breast cancer. Ann Oncol. 1(4):263-8, 1990 Jul.

Riou JF. Grondard L. Petitgenet O. Abitbol M. Lavelle F. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin. Biochemical Pharmacology. 46(5):851-61, 1993 Sep 1.

Rizvi NA. Ng SW. Sullivan D. Eder JP. Schniper LE. Chan VTW. Identification of a point mutation in topoisomerase II cDNA in a mitoxantrone resistant CHO cell line. Proceedings of the American Association for Cancer Research 34:333 #1984 1993

Roche J. Boldog F. Robinson M. Robinson L. Varella-Garcia M. Swanton M. Waggoner B. Fishel R. Franklin W. Gemmill R. Drabkin H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene. 12(6):1289-97, 1996 Mar 21.

Rubin RH. Tsai-Kun LI. Pu Duann. Liu LF. Topoisomerases. in "Drug Resistance" ed Hait W N. Kluwer Academic Publishers, Boston 1996

Saez R. Craig JB. Kuhn JG. Weiss GR. Koeller J. Phillips J. Havlin K. Harman G. Hardy J. Melink TJ. et al. Phase I clinical investigation of amonafide. Journal of Clinical Oncology. 7(9):1351-8, 1989 Sep.

Sami SM. Dorr RT. Alberts DS. Remers WA. 2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent. Journal of Medicinal Chemistry. 36(6):765-70, 1993 Mar 19.

Sams RL. Compadre RL. Castleberry A. Samokyszyn VM. Ronis M. Compadre CM. Quantition of physico-chemical properties affecting the mutagenicity and rates of reduction of nitroaromatics. P 484-7 in "QSAR and Molecular Modelling" ed Sanz F. Giraldo J. Manaut F. Prous Science Publishers 1995.

Schultz P. Olland S. Oudet P. Hancock R. Structure and conformational changes of DNA topoisomerase II visualized by electron microscopy. Proceedings of the National Academy of Science 93:5936-40 1996.

Shan K. Lincoff AM. Young JB. Anthracycline induced cardiotoxicity [Review]. Annals of Internal Medicine 125:47-58 1996.

Sherar M. Liu FF. Pintilie M. Levin W. Hunt J. Hill R. Hand J. Vernon C. van Rhoon G. van der Zee J. Gonzalez DG. van Dijk J. Whaley J. Machin D. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial. International Journal of Radiation Oncology, Biology, Physics. 39(2):371-80, 1997 Sep 1.

Sicheri F. Moarefi I. Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck Nature. 385(6617):602-9, 1997 Feb 13.

Slamon DA. Clark GM. Wong SG. Levin WJ. Ullrich A. McGuire WL. Science 244:707 1989

Smith K. Houlbrook S. Greenall M. Carmichael J. Harris AL. Topoisomerase IIa co-amplification with erbB2 in Human Primary Breast Cancer Cell Lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933 1993

Solyom AM (University of Arizona, Dept of Pharmaceutical Science) unpublished data.

Stevnsner T. Bohr VA. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Carcinogenesis. 14(9):1841-50, 1993 Sep.

Sullivan DM. Latham. MD. Ross WE. Proliferation dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and CHO cells. Cancer Research 47:3973-9 1987.

Sullivan DM. Glisson BS. Hodges PK. Smallwood-Kentro S. Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 25(8):2248-56, 1986 Apr 22.

Superti-Furga G. Gonfloni S. A crystal milestone: the structure of regulated Src. [Review] Bioessays. 19(6):447-50, 1997 Jun.

Takano H Proc American As Cancer Research 34:1983 1993

Tan KB. Dorman TE. Falls, KM. Topoisomerase IIa and IIb genes. Cancer Research 52:231-4 1992.

Tepe JJ. Madalengoitia JS. Slunt KM. Werbovetz KW. Spoors PG. Macdonald TL. Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain. Journal of Medicinal Chemistry 39.2188-96 96.

Thomas W. Spell RM. Ming ME. Holm C. Genetic analysis of the gyrase A-like domain of DNA topoisomerase II of Saccharomyces cerevisiae. Genetics. 128(4):703-16, 1991 Aug.

Tsutsui K. Tsutsui K. Muller MT. The Nuclear Scaffold Exhibits DNA binding Sites Selective for Supercoiled DNA. Journal of Biological Chemistry 263:7235-41 1988.

Tucker PW. Hazen EE Jr. Cotton FA. Staphylococcal nuclease reviewed: a prototypic study in contemporary enzymology. III. Correlation of the three-dimensional structure with the mechanisms of enzymatic action. Molecular & Cellular Biochemistry. 23(2):67-86, 1979 Jan 26.

van der Zee AG. Hollema H. de Jong S. Boonstra H. Gouw A. Willemse PH. Zijlstra JG. de Vries EG. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51(21):5915-20, 1991 Nov 1.

van Gunsteren WF & Berendsen HJC. Angew Chem International Edition England 29:992-1023 1990

Vikhanskaya F. D'Incalci M. Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. International Journal of Cancer. 61(3):397-401, 1995 May 4.

Wadkins RM. Graves DE. Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids. Nucleic Acids Research 17:9933-46 1989.

Wall. M. Wani, M et al: Plant Antitumor Agents; Journal of the American Chemical Society 88:3888-90 1966

Wang H. Jiang Zg. Wong YW. Dalton WS. Futscher BW. Chan VT Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.Biochem Biophys Res Commun 1997 Aug 18;237(2):217-224

Wang JC. Interaction Between DNA and Escherichia coli protein omega. Journal of Molecular Biology 55(3):523-33, 1971 Feb 14.

Wang JC. DNA topoisomerases. Annual Review of Biochemistry 65:635-92 1996.

Wang Q. Zambetti GP. Suttle DP Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppresser. Molecular Cell Biology 17(1):389-397 1997

Wasserman RA. Wang JC. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res. 54(7):1795-800, 1994 Apr 1.

Webb CD. Latham MD. Lock RB. Sullivan DM. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a CHO cell line. Cancer Research 51:6543-9 1991.

Weiner SJ & Kollman PA. An all atom force field for simulations of proteins and nucleic acids. Journal of Computational Chemistry 7:230-52 1986

Weiner SJ. Kollman PA. Case DA. Singh UC. Ghio C. Alagona G. Profeta S. Weiner P. A new force field for molecular mechanical simulation of nucleic acids and proteins. Journal of the American Chemical Society 106:765-84 1984

Weiss GR. Burris HA. Eckardt JR. Fields S. O’Rourke T. Rodriguez GI. Rothenberg ML. New anticancer agents. Chapter 9, pg 130-146 in "Cancer Chemotherapy and Biological Response Modifiers Annual 15. Pinedo HM. Longo DL. Chabner BA (ed). Elsevier Science 1994.

Wels W. Groner B. Hynes NE. Intervention in receptor tyrosine kinase mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Current Topics in Microbiology and Immunology 213 pt3:113 1996.

Whitacre CM. Zborowska E. Gordon NH. Mackay W. Berger NA. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997 Apr 15;57(8):1425-1428

White JH. Cozzarelli NR. Bauer WR. Helical repeat and linking number of surface wrapped DNA. Science 241:323-7 1988.

Wieland I. Ammermuller T. Bohm M. Totzeck B. Rajewsky MF. Microsatellite instability and loss of heterozygosity at the hMLH1 locus on chromosome 3p21 occur in a subset of nonsmall cell lung carcinomas. Oncology Research. 8(1):1-5, 1996.

Wilson WR. Baguley BC. Wakelin LP. Waring MJ. Interaction of the antitumor drug 4’-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines with nucleic acids. Molecular Pharmacology 20:404-14 1981.

Withoff S. Keith WN. Knol AJ. Coutts JC. Hoare SF. Mulder NH. de Vries EG Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996 Aug;74(4):502-507

Woessner RD. Eng WK. Hofmann GA. Rieman DJ. McCabe FL. Hertzberg RP. Mattern MR. Tan KB. Johnson RK. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res. 4(11-12):481-8, 1992.

Wyckoff E. Natalie D. Nolan JM. Lee M. Hsieh T. Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II. J Mol Biol. 205(1):1-13, 1989 Jan 5.

Wyler B. Shao Y. Schneider E. Cianfriglia M. Scheper RJ. Frey BM. Gieseler F. Schmid L. Twentyman PR. Lehnert M Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. British Journal of Haematology 1997 Apr;97(1):65-75

Yamagishi J. Yoshida H. Yamayoshi M. Nakamura S. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Molecular and General Genetics 204(3):367-73, 1986.

Yin C. Knudson CM. Korsmeyer SJ. Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385(6617):637-40, 1997 Feb 13.

Yokota J. Tsukada Y. Nakajima T. Gotoh M. Shimosato Y. Mori N. Tsunokawa Y. Sugimura T. Terada M. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res. 49(13):3598-601, 1989 Jul 1.

Yoshida H. Nakamura M. Bogaki M. Ito H. Kojima T. Hattori H. Nakamura S. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrobial Agents & Chemotherapy. 37(4):839-45, 1993 Apr.

Zhu CX. Roche CJ. Tse-Dinh YC. Effect of Mg(II) binding on the structure and activity of Escherichia coli DNA topoisomerase I. J Biol Chem 1997 Jun 27;272(26):16206-16210

Zini N. Santi S. Ognibene A. Bavelloni A. Neri LM. Valmori A. Mariani E. Negri C. Astaldi-Ricotti GC. Maraldi NM. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Experimental Cell Research 210:336-48 1994.

Zwelling LA. Chan D. Hinds M. Mayes J. Silberman LE. Blick M. Effect of Phorbol Ester Treatment on Drug Induced Topoisomerase II Mediated DNA Cleavage in Human Leukemia Cells. Cancer Research 48:6625-33 1988.

Zwelling LA. Michaels S. Erickson LC. Ungerleider RS. Nichols M. Kohn KW. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry. 20(23):6553-63, 1981 Nov 10.